Ondine CTO receives Lifetime Achievement Award
Ondine's Dr. Nicolas Loebel receives IPA Lifetime Achievement Award for photodisinfection advancements
Dr. Nicolas Loebel, President and Chief Technology officer of Ondine Biomedical Inc., has been awarded the 2022 Lifetime Achievement Award by the International Photodynamic Association (IPA) at the annual Photodynamic Therapy and Photodiagnostic (PDT-PDD) Symposium in Nancy, France. The Lifetime Achievement Award recognizes Dr. Loebel's significant contributions which have greatly advanced the emerging field of antimicrobial photodynamic therapy (aPDT), also known as photodisinfection.
Dr. Loebel's research and development career spans over 20 years and has resulted in significant advancements in the science and clinical translation of aPDT, which is the foundation of Ondine Biomedical's nasal photodisinfection technology, Steriwave™.
Dr. Loebel has been a leading force in the success of translating photodisinfection from bench to field, demonstrating safety, efficacy, and significant cost savings to healthcare systems. His pioneering work has led to numerous first-of-kind photodisinfection-based medical devices that prevent and treat multidrug-resistance infections without the use of antibiotics.
About Nasal Photodisinfection
Ondine's nasal photodisinfection comprises a two-step process: the application of a proprietary light-activated solution to each nostril using a nasal swab, followed by illumination of the area with a specific wavelength of laser light for less than five minutes. The photodisinfection process works by light exciting the photodynamic solution, causing an oxidative burst that is lethal to pathogens (Watch video here: www.ondinebio.com/technology ) . A key benefit of this approach, unlike with antibiotics, is that pathogens do not develop resistance to the therapy. Photodisinfection is also known in the scientific community as antimicrobial photodynamic therapy (aPDT).
Ondine's nasal photodisinfection has a CE mark for use in the EU and is approved in Canada and several other countries, including the UK, under the name Steriwave ™ . In the US, it has received Qualified Infectious Disease Product designation and Fast Track status from the FDA and is currently undergoing clinical trials for US regulatory approval.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as sinusitis, ventilator-associated pneumonia, burns, and other indications.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
COMPANIES COVERED:
Latest directors dealings
- 15 minutes ago Indivior
- 17 minutes ago Mobico Group
- 21 minutes ago Schroder Income Growth Fund
- 1 hour ago OSB Group
- 1 hour ago RM